Copyright © Inderes 2011 - present. All rights reserved.
Log in to receive notifications.
  • Latest
  • Markets
    • Stock Comparison
    • Financial calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About us
    • Our coverage
    • Team

Annexin Pharmaceuticals

0.331

 

SEK

 

+3.44 %

Less than 1K followers

ANNX

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
+3.44%
-29.08%
-21.71%
-24.16%
-35.06%
+30.51%
-30.78%
-49.7%
-89.65%

Annexin Pharmaceuticals is a biotechnology company with development in the Annexin A5 area. The company's biological drug candidate ANXV – a human recombinant protein, Annexin A5 – is primarily intended for the treatment of patients with damage and inflammation in the blood vessels, but also for cancer. The company has an extensive patent portfolio for the treatment and production of Annexin A5. The company was founded in 2014 and is based in Stockholm.

Read more
Market cap
231.55M SEK
Turnover
20.94K SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Financial calendar
14/5
2025

Interim report Q1'25

15/5
2025

General meeting '25

17/7
2025

Interim report Q2'25

ShowingAll content types
Regulatory press release2 hours ago

Annexin Pharmaceuticals offentliggör Informationsdokument med anledning av förestående företrädesemission

Annexin Pharmaceuticals
Regulatory press release2 hours ago

Annexin Pharmaceuticals publishes Information document in connection with forthcoming rights issue

Annexin Pharmaceuticals
Regulatory press release2/25/2025, 12:45 PM

Kommuniké från extra bolagsstämma i Annexin Pharmaceuticals AB

Annexin Pharmaceuticals

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release2/17/2025, 2:05 PM

Annexin Pharmaceuticals AB: BioStock: Annexin konfirmerar lovande resultat och stärker kassan

Annexin Pharmaceuticals
Press release2/17/2025, 2:05 PM

Annexin Pharmaceuticals AB: BioStock: Annexin confirms promising results and strengthens financial position

Annexin Pharmaceuticals
Regulatory press release2/6/2025, 3:05 PM

Annexin Pharmaceuticals bokslutskommuniké 2024

Annexin Pharmaceuticals
Press release2/6/2025, 3:00 PM

Databasen i Annexins fas 2a-studie inom RVO stängd. Data bekräftar lovande resultat – ger starkt stöd för fortsatt utveckling av läkemedelskandidaten ANXV

Annexin Pharmaceuticals
Press release2/6/2025, 3:00 PM

Database lock completed in Annexin's Phase 2a study in RVO. Data confirms promising results – providing strong support for continued development of the drug candidate ANXV

Annexin Pharmaceuticals
Regulatory press release2/6/2025, 2:55 PM

KALLELSE TILL EXTRA BOLAGSSTÄMMA I ANNEXIN PHARMACEUTICALS AB (PUBL)

Annexin Pharmaceuticals
Regulatory press release2/6/2025, 2:47 PM

Annexin beslutar om företrädesemission om cirka 50 MSEK, säkerställd till cirka 80 procent, villkorat av extra bolagsstämmas godkännande

Annexin Pharmaceuticals
Regulatory press release2/6/2025, 2:47 PM

Annexin resolves on a rights issue of approximately SEK 50 million, secured to approximately 80 percent, subject to approval by the Extraordinary General Meeting

Annexin Pharmaceuticals
Regulatory press release11/8/2024, 12:00 PM

Annexins valberedning utsedd inför årsstämman 2025

Annexin Pharmaceuticals
Press release11/4/2024, 10:00 AM

Annexin Pharmaceuticals AB: Annexin Pharmaceuticals will present at the BioStock Life Science Summit, November 21

Annexin Pharmaceuticals
Press release11/4/2024, 10:00 AM

Annexin Pharmaceuticals AB: Annexin Pharmaceuticals presenterar på BioStock Life Science Summit 21 november

Annexin Pharmaceuticals
Press release10/18/2024, 9:50 AM

Redeye: Annexin Q3 - Presented positive top-line data during the quarter

Annexin Pharmaceuticals
Regulatory press release10/17/2024, 6:30 AM

Annexin Pharmaceuticals delårsrapport januari-september 2024

Annexin Pharmaceuticals
Regulatory press release10/9/2024, 2:30 PM

Kommuniké från extra bolagsstämma i Annexin Pharmaceuticals AB

Annexin Pharmaceuticals
Regulatory press release9/20/2024, 8:00 AM

KALLELSE TILL EXTRA BOLAGSSTÄMMA I ANNEXIN PHARMACEUTICALS AB (PUBL)

Annexin Pharmaceuticals
Press release8/27/2024, 12:53 PM

Annexin Pharmaceuticals AB: BioStock: Annexin: Kan ANXV ersätta anti-VEGFs?

Annexin Pharmaceuticals
Press release8/27/2024, 12:53 PM

Annexin Pharmaceuticals AB: BioStock: Annexin: Could ANXV replace anti-VEGFs?

Annexin Pharmaceuticals
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

  • Latest
  • Markets
    • Stock Comparison
    • Financial calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About us
    • Our coverage
    • Team

Privacy preferences

Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.